$Moderna, Inc.(MRNA)$ Moderna (MRNA) has seen a meteoric rise in growth and become a household name as one of the leading COVID-19 vaccine manufacturers. However, the stock has slumped as of late — down around 60% from a September 2021 high of nearly $450. According to Jefferies’ (JEF) Michael Yee, managing director covering health-care equity research, the pharma and biotech company’s stock is in a rut due to not being able to meet the market’s expectations. “What I think in 2022 is that the overly high expectations and significant valuation is going to lead to challenges in 2022,” Yee said. “And I think there's going to be a lot of money flow out of this name as people digest what's next for the company beyond COVID vaccines. And I think that'